VENCLEXTA

This brand name is authorized in United States. It is also authorized in Australia, Brazil, Canada, Ecuador, Hong Kong SAR China, Israel, Japan, New Zealand, Singapore.

Active ingredients

The drug VENCLEXTA contains one active pharmaceutical ingredient (API):

1	Venetoclax UNII N54AIC43PW - VENETOCLAX
	Venetoclax is a potent, selective inhibitor of B-cell lymphoma (BCL)-2, an anti-apoptotic protein. Overexpression of BCL-2 has been demonstrated in CLL and AML cells where it mediates tumour cell survival and has been associated with resistance to chemotherapeutics. Venetoclax binds directly to the BH3-binding groove of BCL-2, displacing BH3 motif-containing pro-apoptotic proteins like BIM, to initiate mitochondrial outer membrane permeabilization (MOMP), caspase activation, and programmed cell death.
	Read more about Venetoclax

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
VENCLEXTA Film coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01XX52		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents
Discover more medicines within L01XX52

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11624T, 11630D, 11639N, 11648C, 12188L, 12199C, 12205J
BR	Câmara de Regulação do Mercado de Medicamentos	543718100003502, 543718100003602, 543718100003702, 543718100003802
CA	Health Products and Food Branch	02458039, 02458047, 02458055, 02458063
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	5500-MEE-0920, 5506-MEE-0920, 5514-MEE-0920
HK	Department of Health Drug Office	65283, 65284, 65285
IL	מִשְׂרַד הַבְּרִיאוּת	7986, 7987, 7988
JP	医薬品医療機器総合機構	4291062F1020, 4291062F2027, 4291062F3023
NZ	Medicines and Medical Devices Safety Authority	18920, 18928, 18929, 19322
SG	Health Sciences Authority	15265P, 15266P, 15267P
US	FDA, National Drug Code	0074-0561, 0074-0566, 0074-0576